PDI names interim CEO
Executive Summary
Exec VP and Chief Administrative Officer Larry Ellberger named interim CEO of PDI following the resignation of Charles Saldarini, the company announces Oct. 21. Saldarini is resigning, effective immediately, after 18 years with PDI serving as President, CEO and Vice Chairman. Ellberger previously acted as Director and Chairman of PDI's Audit Committee. Before joining PDI, Ellberger served as CFO and interim CEO of W.R. Grace...
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.